APUS
Apimeds Pharmaceuticals US, Inc
There isn't enough reported data to score APUS yet.
APUS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
APUS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
APUS PE Valuation
APUS has no meaningful PE right now: it lost money over the past year.
APUS Forward outlook
There aren't enough analyst estimates for APUS to show an outlook.
APUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$47.46 | -$34.49 |
| Q2 2025 | -$36.08 | -$24.86 |
| Q1 2025 | -$13.62 | -$5.66 |
| Q4 2024 | -$10.96 | -$4.83 |
| Q3 2024 | -$12.97 | -$10.72 |
APUS lost $47.46 per share over the past year, and its loss has widened in each of the last three quarters.
APUS Quarterly Revenue
APUS's revenue is shrinking: $0 last quarter.
APUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.1M | -$2.1M |
| Q4 2025 | -$3.8M | -$3.7M |
| Q3 2025 | -$1.7M | -$1.6M |
| Q1 2025 | -$20.3K | +$242.8K |
| Q4 2024 | -$99.6K | +$241K |
| Q3 2024 | -$186.8K | +$85.7K |
| Q2 2024 | -$184.1K | -$178.2K |
| Q1 2024 | -$263.1K | -$254.3K |
APUS has burned cash in almost every quarter: −$13M over the past year, against −$490,739 the year before.
APUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +162K shares |
| 1 year | +2068% | +1.6M shares |
| 3 years | +1250% | +1.6M shares |
APUS has 2M diluted shares, up 2068% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
APUS Net Leverage
APUS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
APUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.3 | Neutral |
| Stochastic | 13.8 | Oversold |
APUS's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
APUS PE vs Healthcare Sector
APUS has no meaningful PE right now: it lost money over the past year.
APUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.80 | 40% below |
| 20 week MA | $4.39 | 48% below |
| 50 week MA | $11.6 | 80% below |
APUS is in a downtrend: it's below all three of its weekly moving averages, and 80% below its 50-week average.
APUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $22.0 | $17.8 | -19% |
| 2026 YTD | $17.8 | $2.27 | -87% |
APUS has finished every year since 2025 lower, and it's down 87% so far in 2026.